A physician reported that in the clinical trial of evaluating the safety of an ophthalmic gas during intravitreal injection a patient experienced rhegmatogenous retinal detachment, cataract development, blurred vision with dark shadow floating in their right eye, the conjunctiva of the right eye was slightly congested, ametropia and patient underwent extra scleral pressure of right eye, phacoemulsification, intraocular lens implantation, vitreous cavity injection, vitrectomy, vitreous puncture, drug injection, membrane stripping before repair of complex retinal detachment, retinal laser photocoagulation and internal pressure repair of retinal detachment (right eye).The patient was given with aminoglycoside antibiotic ointment, corticosteroids eye drops, anticholinergic eye gel, quinolone antibiotics eye drops, aminoglycoside antibiotic injection, antimuscarinic eye drops, corticosteroids suspension eye drops.The patient was generally in good condition, did not complain of discomfort, and the dressing was clean and discharged with medicine.
|
Additional information was provided in sections h.6 and h.10.The perfluoropropane (c3f8) gas tank was not returned for evaluation.A review of the batch production record for lot showed no unusual manufacturing issues.A review of the complaint records showed no other complaints against the lot number.A review of confirmed complaints for patients that have experienced retinal detachment, cataracts, blurred vision, or dark shadows showed no complaints since the beginning of 2015.An analysis of the retain samples of lot numbers showed that the product was perfluoropropane (pfp) and meet all release criteria.The procedure does not comply with the directions for use (dfu).The root cause of the reported event cannot be determined.Manufacturer will continue to monitor data for evidence of adverse trending and take further action, as appropriate.The manufacturer internal reference number is: (b)(4).
|